Fidelis Capital Partners LLC Buys 164 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Fidelis Capital Partners LLC boosted its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 6.1% in the third quarter, Holdings Channel reports. The institutional investor owned 2,855 shares of the medical device company’s stock after buying an additional 164 shares during the period. Fidelis Capital Partners LLC’s holdings in Cooper Companies were worth $301,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Innealta Capital LLC bought a new position in Cooper Companies in the 2nd quarter valued at approximately $25,000. Covestor Ltd raised its holdings in Cooper Companies by 305.9% in the 1st quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock valued at $28,000 after buying an additional 208 shares during the last quarter. Crewe Advisors LLC raised its holdings in Cooper Companies by 286.4% in the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock valued at $30,000 after buying an additional 252 shares during the last quarter. Tortoise Investment Management LLC raised its holdings in Cooper Companies by 75.4% in the 2nd quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock valued at $34,000 after buying an additional 169 shares during the last quarter. Finally, Clearstead Trust LLC bought a new position in Cooper Companies in the 1st quarter valued at approximately $36,000. Institutional investors own 24.39% of the company’s stock.

Insider Activity at Cooper Companies

In other Cooper Companies news, COO Daniel G. Mcbride sold 114,992 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the sale, the chief operating officer now owns 44,696 shares in the company, valued at approximately $4,714,534.08. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Cooper Companies news, COO Daniel G. Mcbride sold 114,992 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the sale, the chief operating officer now owns 44,696 shares in the company, valued at approximately $4,714,534.08. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Brian G. Andrews sold 24,788 shares of the business’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the sale, the chief financial officer now owns 6,614 shares of the company’s stock, valued at $700,422.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 256,373 shares of company stock valued at $27,637,427. 2.00% of the stock is owned by company insiders.

Cooper Companies Stock Performance

Shares of COO stock opened at $105.20 on Thursday. The company has a market cap of $20.95 billion, a price-to-earnings ratio of 58.44, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98. The Cooper Companies, Inc. has a 52 week low of $77.01 and a 52 week high of $112.38. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The firm has a 50 day moving average of $106.34 and a 200-day moving average of $96.91.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.91 by $0.05. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.84 EPS. On average, equities analysts forecast that The Cooper Companies, Inc. will post 3.65 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Wells Fargo & Company raised their price objective on shares of Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a report on Thursday, August 29th. Robert W. Baird raised their price target on shares of Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a report on Thursday, August 29th. Morgan Stanley raised their price target on shares of Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a report on Tuesday, September 10th. Jefferies Financial Group upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating and raised their price target for the stock from $107.00 to $115.00 in a report on Tuesday, July 16th. Finally, Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a report on Thursday, August 29th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $117.00.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.